Research Article
Clinicopathologic and Prognostic Significance of Body Mass Index (BMI) among Breast Cancer Patients in Western China: A Retrospective Multicenter Cohort Based on Western China Clinical Cooperation Group (WCCCG)
Table 5
Multivariable Cox regression for DFS of breast cancer patients.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disease-free survival (DFS) was defined as the time from surgery to the date of the first locoregional recurrence, first distant metastasis, or death from any cause. †Multivariate analysis adjusted by BMI, age at diagnosis, tumor size, number of positive ALN, nuclear grade, status of ER, PR, and HER2, surgery, chemotherapy, endocrine therapy, and radiotherapy. NW, normal weight (BMI, 18.5 to 24.9 kg/m2); UW, underweight (BMI, <18.5 kg/m2); OW, overweight and obese (BMI, >25 kg/m2); HR, hazard ratio; CI, confidence intervals; ALN, axillary lymph nodes; ER, estrogen-receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BCS, breast conserving surgery; MRM, modified radical mastectomy. |